Vega-Anaya GC, Hernández-Lomelí A, Hernández-Montiel HL

Language: Spanish
References: 39
Page: 515-522
PDF size: 169.12 Kb.

ABSTRACT

Type 1 diabetes mellitus (DM1) is an autoimmune disease characterized by a lack of insulin production by β pancreatic cells. Immunological mechanisms play a key role in DM1 physiopathology, even in asymptomatic patients where different autoantibodies directed against several components of β cells have been found. The human leucocitary antigen, islet cells autoantibodies, insulin autoantibodies, glutamic acid decarboxilase autoantibodies and the rapid intravenous glucose tolerance test can be used to identify individuals with high risk for developing DM1. Ganglioside GM2-1 and the tyrosine phosphatase enzyme (IA2/ICA512) antigens determination are also employed to assess DM1 individual risk. This risk is significantly higher when three or four autoantibodies are found. Nowadays, the islet cell autoantibodies are employed as markers for DM1. This work analyzes the immunological aspects related to DM1, and highlights recent developments in this field.

REFERENCES

1. Yoon JW, Jun HS. Autoimmune destruction of pancreatic β cells. Am J Therap 2005;12(6):580-591.

2. Kumar V, Abbas A, Fausto N. Robbins. Patología humana. Sexta edición. Madrid, España: Elsevier; 2005.

3. Allison J, Strasser A. Mechanisms of beta cell death in diabetes: a minor role for CD95. Proc Natl Acad Sci 1998;95(23):13818-13822.

4. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-su K, et al. Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest 2002;109(1):131-140.

5. Mandrup-Poulsen T. β cell apoptosis. Diabetes 2001;50(Suppl 1):s58-s63.

6. Apostolou I, Hao Z, Rajewsky K, von Boehmer H. Effective destruction of fas-deficient insulin-producing β cells in type 1 diabetes. J Exp Med 2003; 198(7):1103-1106.

7. Hamilton WE, Palmer S, Charlton B, Slattery R. Beta cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci 2003;100:6688-6693.

8. Verdaguer J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaría P. Spontaneous autoimmune diabetes in monoclonal t cell nonobese diabetic mice. J Exp Med 1997;186(10):1663-1676.

9. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+, CD25+ T regulatory cells control anti-islet CD8+ T cells through TGFβ-TGFβ receptor interactions in type 1 diabetes. Proc Natl Acad Sci 2003;100(19):10878-10883.

10. Panagiotopoulos C, Qin H, Tan R, Verchere CB. Identification of a beta-cellspecific HLA class I restricted epitope in type 1 diabetes. Diabetes 2003;52 (11):2647-2651.

11. Tisch R, Wang B, Atkinson MA, Serreze DV, Friedline R. A glutamic acid decarboxylase 65-specific Th2 cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. J Immunol 2001;166(11):6925-6936.

12. Rajagopalan G, Kudva YC, Chen L, Wen L, David CS. Autoimmune diabetes in HLA-DR3/DQ8 transgenic mice expressing the co-stimulatory molecule B7-1 in the β cells of islets of Langerhans. Int Immunol 2003;15(9):1035-1044.

13. Achenbach P, Bonifacio E, Koczwara K, Ziegler A. Natural history of type 1 diabetes. Diabetes 2005;54(Suppl 2):S25-S31.

14. Amrani A, Verdaguer J, Thiessen S, Bou S, Santamaría P. IL1α, IL1β, and IFNγ mark β cells for fas-dependent destruction by diabetogenic CD4+ T lymphocytes. J Clin Inv 2000;105:459-468.

15. Lee L, Xu B, Michie S, Beilhack G, Warganich T, Turley S, et al. The role of TNFα in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. Proc Natl Acad Sci 2005;102(44):15995-16000.

16. Chong MM, Chen Y, Darwiche R, Dudek NL, Irawaty W, Santamaría P, et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from Cd8+ T cell-mediated autoimmune destruction. J Immunol 2004; 172:5714- 5721.

17. Standifer NE, Panagiotopoulos C, Tan R. Current approaches for the prediction and identification of CD8 T-cell epitopes in type 1 diabetes. Curr Opin Endocrinol Diab 2005;12(4):298-230.

18. Suárez-Pinzon WL, Rabinovitch A. Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits. Int J Exp Diabetes Res 2001; 2(1):3-17.

19. Hartemann A, Boirtard C. T-cell regulation in murine and human autoimmune diabetes: the role of TH1 and TH2 cell. Diabetes Metab 1997;23(5):377-385.

20. Moore A, Grima J, Han B, Santamaría P. Tracking the recruitment of diabetogenic CD8-T-cells to the pancreas in real time. Diabetes 2004;53(6):1459-1466.

21. Falcone M, Yeung B, Tucker L, Rodríguez E, Sarvetnick N. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer t cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus. J Exp Med 1999;190(7):963-972.

22. Flores-Aldana M, Peralta-Zaragoza O, Barquera-Cervera S. El paradigma inmune Th1-Th2: un vínculo entre obesidad, aterosclerosis y diabetes mellitus. Clin Invest Arterioscl 2005;17(5):232-248.

23. Graser R, DiLorenzo T, Wang F, Christianson G, Chapman H, Roopenian D, et al. Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol 2000;164(7):3913-3918.

24. Zhang Y, O’Brien B, Trudeau J, Tan R, Santamaría P, Dutz JP. In situ cell death promotes priming of diabetogenic CD8 T lymphocytes. J Immunol 2002; 168(3):1466-1472.

25. Anderson B, Park Bj, Verdaguer J, Amrani A, Santamaría P. Prevalent CD81 T cell response against one peptide/MHC complex in autoimmune diabetes. Proc Natl Acad Sci 1999;96(16):9311-9316.

26. Xiao S, Hu O, Kristan JM, Costa C, Shen Y, Gero D, et al. Significant role for Fas in the pathogenesis of autoimmune diabetes. J Immunol 2000;164(5):2523-2532.

27. Álvarez EC, Darias GA, López-Guzmán A, Pallardo SL. Etiopatogenia de la diabetes mellitus. Medicina 2000;8:991-1000.

28. García BH. Factores de riesgo y prevención en diabetes mellitus tipo 1: actualización. Rev Chil Pediatr 2001;72(4):285-291.

29. Notkins A, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001;108(9):1247-1252.

30. Diez J, Park Y, Zeller M, Brown D, Garza D, Ricordi C, et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes 2001; 50(4):895-900.

31. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000;342(5):301-307.

32. Lieberman S, Evans A, Han B, Takaki T, Vinnitskaya Y, Caldwell J, et al. Identification of the cell antigen targeted by a prevalent population of pathogenic CD8 T cells in autoimmune diabetes. Proc Natl Acad Sci 2003;100(14):8384-8388.

33. Ibarra O, Alpízar S, Martínez M, Jiménez S, Mendoza M, González B, et al. Antecedentes familiares de diabetes en diabéticos tipo 1. Rev Endocrinol Nut 2000;8:100-104.

34. Like A, Rossini A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976;193(4251):415-417.

35. Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF Jr. Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci 1977;74(6): 2485-2489.

36. Vives P, Gallart T, Algarra L, Goméz B, Fresno M, Garrido F, et al. Inmunología. Disponible en http:// www.sepeap.es/libros/farreras13/SECCION/ SEC20.PDF

37. Grupo de Trabajo de Prediabetes Tipo 1 de la Sociedad Española de Diabetes. Prediabetes y diabetes tipo 1 de reciente diagnóstico. Madrid, España: Mayo; 2006.

38. Aoki K, Taniyama M, Nagayama C, Oikawa Y, Shimada A. T cell immunity to glutamic acid decarboxylase in fulminant type 1 diabetes without significant elevation of serum amylase. Ann N Y Acad Sci 2006;1079:181-185.

39. Rich S, Concannon P, Erlich H, Julier C, Morahan G, Nerup J, et al. The type 1 diabetes genetics consortium. Ann N Y Acad Sci 2006;1079:1-8.